Cochrane Abstracts
Rituximab for thyroid‐associated ophthalmopathy
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Rituximab for Thyroid‐associated Ophthalmopathy." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433649/all/Rituximab_for_thyroid‐associated_ophthalmopathy.
Rituximab for thyroid‐associated ophthalmopathy. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433649/all/Rituximab_for_thyroid‐associated_ophthalmopathy. Accessed November 24, 2024.
Rituximab for thyroid‐associated ophthalmopathy. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433649/all/Rituximab_for_thyroid‐associated_ophthalmopathy
Rituximab for Thyroid‐associated Ophthalmopathy [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 November 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433649/all/Rituximab_for_thyroid‐associated_ophthalmopathy.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rituximab for thyroid‐associated ophthalmopathy
ID - 433649
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433649/all/Rituximab_for_thyroid‐associated_ophthalmopathy
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
